热门资讯> 正文
Edwards Lifesciences基于AMPS M3、EVOQUE瓣膜置换的数据
2025-10-28 03:51
- Edwards Lifesciences (NYSE:EW) is up ~7% in Monday trading after releasing new data on its SAPIEN M3 and EVOQUE heart valve replacement systems.
- Results from the ENCIRCLE trial of SAPIEN M3, a transfemoral transcatheter mitral valve replacement (TMVR) system, showed low heart failure hospitalization and death rates, as well as significant mitral regurgitation elimination.
- Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement (TTVR) dataset, found lower pacemaker rates (14.9%) and minimal major or life-threatening bleeding rates (1.3%) at 30 days compared to the TRISCEND II pivotal trial that read out in October 2024.
- While EVOQUE is approved in the US, SAPIEN M3 is still awaiting US FDA clearance.
More on Edwards Lifesciences
- Edwards Lifesciences: Inflection Incoming, But When?
- Edwards Lifesciences: A Market Leader Stuck In 'Hold' Mode Despite Solid Growth
- Edwards Lifesciences: Gradually Winning My Investment Heart
- Edwards Lifesciences slips as Oppenheimer downgrades on upcoming data
- Edwards Lifesciences upgraded at Evercore on upcoming 'topline inflection'
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
